Benitec Biopharma Inc. Common Stock (BNTC)

Price$10.82

Value ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-27.95%

Price vs S&P 500 (4W)-8.24%

VGM Score30.06

Market Capitalization$397.14M

All Metrics

Book Value / Share (Quarterly)$3.57

P/TBV (Annual)40.75x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.85

Price vs S&P 500 (YTD)-25.11%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-20671.43%

EPS (TTM)$-1.11

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-1.11

EPS (Annual)$-1.05

ROI (Annual)-46.28%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-16368.59%

Cash / Share (Quarterly)$3.60

ROA (Last FY)-41.83%

EBITD / Share (TTM)$-1.21

ROE (5Y Avg)-2121.74%

Operating Margin (TTM)-20714.29%

Cash Flow / Share (Annual)$-1.96

P/B Ratio4.24x

P/B Ratio (Quarterly)3.93x

Net Income / Employee (Annual)$-1,995,600

EV / Revenue (TTM)4323.67x

Net Interest Coverage (TTM)-42.47x

ROA (TTM)-44.04%

EPS Incl Extra (Annual)$-1.05

Current Ratio (Annual)10.57x

Quick Ratio (Quarterly)46.72x

3-Month Avg Trading Volume0.14M

52-Week Price Return-25.85%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.12

P/S Ratio (Annual)4964.20x

Asset Turnover (Annual)0.02x

52-Week High$17.15

Operating Margin (5Y Avg)-16055.53%

EPS Excl Extra (Annual)$-1.05

CapEx CAGR (5Y)-29.03%

Tangible BV CAGR (5Y)-57.08%

26-Week Price Return-12.02%

Quick Ratio (Annual)10.46x

13-Week Price Return3.31%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)46.95x

Enterprise Value$302.66M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-33.13%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-24450.00%

Cash / Share (Annual)$5.10

3-Month Return Std Dev52.61%

Gross Margin (5Y Avg)94.40%

Net Income / Employee (TTM)$-2,572,800

ROE (Last FY)-46.28%

Net Interest Coverage (Annual)-68.59x

EPS Basic Excl Extra (Annual)$-1.05

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.11

Receivables Turnover (Annual)2.67x

ROI (TTM)-45.91%

P/S Ratio (TTM)5673.37x

Pretax Margin (5Y Avg)-16368.59%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.12

Price vs S&P 500 (52W)-54.06%

Year-to-Date Return-14.18%

5-Day Price Return2.94%

EPS Normalized (Annual)$-1.05

ROA (5Y Avg)-184.34%

Net Profit Margin (Annual)-24450.00%

Month-to-Date Return-4.07%

Cash Flow / Share (TTM)$-14.00

EBITD / Share (Annual)$-1.13

Operating Margin (Annual)-23850.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-2121.74%

EPS Basic Excl Extra (TTM)$-1.11

P/TBV (Quarterly)40.75x

P/B Ratio (Annual)1.45x

Pretax Margin (TTM)-20671.43%

Book Value / Share (Annual)$4.70

Price vs S&P 500 (13W)-6.44%

Beta0.30x

P/FCF (Annual)105.06x

Revenue / Share (TTM)$0.00

ROE (TTM)-45.91%

52-Week Low$9.85

vGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q3 26-0.24est. -0.28

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.38

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
BNTCBenitec Biopharma Inc. Common Stock	F	—	C	$10.82
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Benitec Biopharma is a clinical-stage biotechnology company developing novel genetic medicines designed to provide one-time curative treatments. The company's lead program, BB-301, is a silence-and-replace therapeutic targeting Oculopharyngeal Muscular Dystrophy (OPMD), a rare, chronic genetic disorder with no currently effective treatments.